The Latest Breaking News on Pharma

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The World Health Organization says that fighters in Sudan have occupied the national public laboratory holding samples of diseases including polio and measles, creating an "extremely, extremely dangerous" situation.

ALLpaQ recognised for outstanding international trade after role in US vaccine roll-out

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Canada’s Families Minister Karina Gould reacted to the US legal battle over mifepristone the day before the US Supreme Court ruling

WASHINGTON — The U.S. Supreme Court blocked a Texas judge’s restrictions on a widely used abortion pill from taking effect, keeping the drug fully available while a legal fight goes forward.

Federal judge in Texas ruled in early April to suspend FDA-approved mifepristone used in more than half of abortions in US

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

The biopharmaceutical industry has been grappling with various challenges, including inflation, the Fed’s hawkish stance, and new regulatory concerns. Hence, it could be wise to avoid Syndax Pharmaceuticals (SNDX), Senseonics Holdings (SENS), and Sio Gene Therapies (SIOX) due to their bleak fundamentals. Keep reading….

Depression drug stock Intra-Cellular Therapies is up over 14% in April and 36% since mid-March.

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals (DAWN), Northwest Biotherapeutics (NWBO), and Ocugen (OCGN), with bearish momentum, could be avoided in April. Read on….